These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11316962)

  • 21. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.
    Himelhoch S; Taylor SF; Goldman RS; Tandon R
    Biol Psychiatry; 1996 Feb; 39(3):227-9. PubMed ID: 8837987
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta.
    Sumiyoshi T; Higuchi Y; Itoh T; Matsui M; Arai H; Suzuki M; Kurachi M; Sumiyoshi C; Kawasaki Y
    Psychiatry Res; 2009 Jun; 172(3):180-3. PubMed ID: 19386475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of effort, cognitive expectancy appraisals and coping style in the maintenance of the negative symptoms of schizophrenia.
    Avery R; Startup M; Calabria K
    Psychiatry Res; 2009 May; 167(1-2):36-46. PubMed ID: 19339056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Schizophrenic disorders--does cognitive dysfunction relate to characteristics of course and psychopathology of the illness?].
    Wciórka J; Bembenek A; Hintze B; Kühn-Dymecka A
    Psychiatr Pol; 2006; 40(5):867-84. PubMed ID: 17217232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Executive impairment among the functionally dependent: comparisons between schizophrenic and elderly subjects.
    Royall DR; Mahurin RK; True JE; Anderson B; Brock IP; Freeburger L; Miller A
    Am J Psychiatry; 1993 Dec; 150(12):1813-9. PubMed ID: 8238635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients.
    Zhang XY; Chen DC; Xiu MH; Yang FD; Haile CN; Kosten TA; Kosten TR
    J Clin Psychiatry; 2012 Jul; 73(7):1025-33. PubMed ID: 22901352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormal subjective experiences in schizophrenia: its relationships with neuropsychological disturbances and frontal signs.
    Cuesta MJ; Peralta V; Juan JA
    Eur Arch Psychiatry Clin Neurosci; 1996; 246(2):101-5. PubMed ID: 9063905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of negative symptoms in the context of cognitive remediation for schizophrenia.
    Farreny A; Aguado J; Ochoa S; Haro JM; Usall J
    Schizophr Res; 2013 Oct; 150(1):58-63. PubMed ID: 23993864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impairments of executive/attentional functions in schizophrenia with primary and secondary negative symptoms.
    Brazo P; Delamillieure P; Morello R; Halbecq I; Marié RM; Dollfus S
    Psychiatry Res; 2005 Jan; 133(1):45-55. PubMed ID: 15698676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance.
    Brissos S; Dias VV; Balanzá-Martinez V; Carita AI; Figueira ML
    Schizophr Res; 2011 Jul; 129(2-3):133-6. PubMed ID: 21514793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the dysexecutive syndrome in schizophrenia.
    Evans JJ; Chua SE; McKenna PJ; Wilson BA
    Psychol Med; 1997 May; 27(3):635-46. PubMed ID: 9153684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of cognitive and functional improvement and normalization after cognitive remediation in patients with schizophrenia.
    Vita A; Deste G; De Peri L; Barlati S; Poli R; Cesana BM; Sacchetti E
    Schizophr Res; 2013 Oct; 150(1):51-7. PubMed ID: 23998953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia.
    Woon PS; Chia MY; Chan WY; Sim K
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):463-8. PubMed ID: 20109511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites.
    Harvey PD; Howanitz E; Parrella M; White L; Davidson M; Mohs RC; Hoblyn J; Davis KL
    Am J Psychiatry; 1998 Aug; 155(8):1080-6. PubMed ID: 9699697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability and change in symptoms, cognition, and community outcome in schizophrenia.
    Miles AA; Heinrichs RW; Ammari N; Hartman L; McDermid Vaz S; Muharib E
    Schizophr Res; 2014 Feb; 152(2-3):435-9. PubMed ID: 24080456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia.
    Kontis D; Theochari E; Kleisas S; Kalogerakou S; Andreopoulou A; Psaras R; Makris Y; Karouzos C; Tsaltas E
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1333-41. PubMed ID: 20691745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting quality of life impairment in chronic schizophrenia from cognitive variables.
    Ritsner MS
    Qual Life Res; 2007 Aug; 16(6):929-37. PubMed ID: 17404898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
    Minzenberg MJ; Poole JH; Benton C; Vinogradov S
    Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care.
    Vita A; Deste G; Barlati S; De Peri L; Giambra A; Poli R; Keefe RS; Sacchetti E
    Schizophr Res; 2013 May; 146(1-3):217-23. PubMed ID: 23510596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms.
    Gurpegui M; Alvarez E; Bousoño M; Ciudad A; Carlos Gómez J; Olivares JM
    Eur Neuropsychopharmacol; 2007 Nov; 17(11):725-34. PubMed ID: 17543505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.